The oncology drug development veteran has been hired by former colleague Daniel O’Day as Gilead looks to improve its R&D hit rate.
Gilead has poached Sanofi’s Dietmar Berger to be its new chief medical officer and oversee its global development and medical affairs organizations, as it looks to reset after a string of late-stage drug failures.
Berger is currently chief medical officer and global head of development at Paris-based Sanofi, but...
After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.
Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.
Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.
